Date: Aug. 27, 2010

Re: Current Master Clinical Trial Agreement

Name of the company, sponsor (Agreement Period)

- **Abbott Laboratories** (10/08/09 – 10/08/12)
- **Abbott Cardiovascular Systems Inc, Abbott Vascular Solutions Inc., Abbott Vascular Inc.** (07/09/09 – until terminated pursuant to Section 9.2)
- **Amgen Inc.** (N/A)
- **Astellas Pharma US, Inc,** (05/09/07 – 06/30/09)
- **Bayer Pharmaceuticals Corporation** (05/14/08 – 05/14/13)
- **Biogen, Inc.** (07/06/99 – N/A)
- **Bristol-Myers Squibb Medical Imaging** (06/21/04 – until the completion of the last Study to be performed)
- **Celgene Corporation** (07/16/08 – 07/16/13)
- **Cook Biotech Incorporated** (10/30/06 - 10/30/13)
- **DuPont Pharmaceuticals Company** (05/08/01 – until terminated pursuant to Section 1B)
- **Genzyme Corporation** (01/01/03 – until it is mutually terminated)
- **GlaxoSmithKline /SmithKline Beecham Corporation** (10/07/03 – until terminated as provided in Section 4)
- **Gilead Sciences, Inc.** (05/17/07 – 5/17/14)
- **ILEX Products, Inc.** (07/16/04 – N/A)
- **Millennium Pharmaceuticals** (9/28/09 – N/A)
- **Novartis** (12/01/05 – 12/01/10)
- **Novo Nordisk Inc.** (05/29/09 – until terminated as provided in Section 4)

- **Pfizer** Global Pharmaceuticals
  1. Master Clinical Study Agreement (05/01/06 – 4/30/11)
  2. Master Investigator-Initiated Research Agreement (Only For Observational and Post-Marketing Drug Studies, doesn’t cover basic science agreement) (04/28/06 – 04/28/11)

- **Roche** Pharmaceuticals – Palo Alto, a division of Syntex /Hoffmann-La Roche Inc. (03/07/97 – N/A)

- **Schering-Plough** Research Institute (3/2/10 – N/A)

- **Sanofi-aventis** U.S. Inc. (02/05/07 – 02/05/12)

- **Tanox, Inc.** (07/16/02 – until terminated pursuant to Section 1b)